Skip to content
  • ABOUT US
  • SCIENCE
  • TECHNOLOGY PLATFORM
  • NEWS
  • COVID-19
Menu
  • ABOUT US
  • SCIENCE
  • TECHNOLOGY PLATFORM
  • NEWS
  • COVID-19

Pages

  • COVID-19
  • SiteMap
  • Mode Of Action
  • Our Science
  • CONTACT US
  • NEWS
  • TECHNOLOGY PLATFORM
  • SCIENCE
  • ABOUT US
  • HOME

Categories

  • Publications
  • Posters
  • News

Posts

  • Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
  • Pangaea Oncology Signs 1.1 Mln contract with In3BIO
  • Anti-IN01 antibodies significantly improve the activity of RET, BRAF, MEK and PI3K kinase inhibitors in preclinical models
  • Anti-EGF antibodies generated by vaccination significantly improve the activity of kinase inhibitors in preclinical models
  • Anti-EGF antibodies increase the effect of ALK and MEK inhibitors in ALK and KRAS NSCLC and CRC cell lines
  • Antitumor effects of anti-EGF antibodies generated by vaccination in NSCLC tumor cells
  • Anti–Epidermal Growth Factor vaccine antibodies enhance the efficacy of tyrosine kinase inhibitors and delay the emergence of resistance in EGFR mutant lung cancer cells
  • The effect of EGF-Pathway Targeted Immunization (EGF-PTI) on STAT3 and cancer stem cells in EGFR mutant NSCLC cells
  • Pathway Targeted Immunotherapy: Rationale and evidence of durable clinical responses with a novel, EGF-directed agent for advanced NSCLC
  • ABOUT US
  • SCIENCE
  • TECHNOLOGY PLATFORM
  • NEWS
  • CONTACT US
Menu
  • ABOUT US
  • SCIENCE
  • TECHNOLOGY PLATFORM
  • NEWS
  • CONTACT US

Copyright 2020 In3Bio Group of Companies
All rights reserved.